PR Newswire Clinical TrialsOriginal article
Sebela Pharmaceuticals to Present Positive Phase 3 Tegoprazan Data in Non-Erosive Reflux Disease (NERD) at the American College of Gastroenterology (ACG) 2026 Meeting
Phase 3positiveTegoprazanPositive
AI Analysis
Summary
Sebela Pharmaceuticals reported positive Phase 3 data for Tegoprazan in non-erosive reflux disease, demonstrating clinical improvement in both heartburn and regurgitation symptoms, positioning it as the first P-CAB with such efficacy in NERD treatment.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Tegoprazan demonstrated clinical improvement in both heartburn and regurgitation in randomized, double-blind, placebo-controlled Phase 3 trial
Importance:7/10
Sentiment:
0.85
Phase 3 datapositive resultsNERDP-CABgastroenterologyACG conference
Read the original article
Published by PR Newswire Clinical Trials on October 11, 2026 5:00 PM